Background/Objectives: Image-guided adaptive brachytherapy is a standard modality in the treatment of locally advanced cervical cancer. However, the availability of isotope-based brachytherapy is limited in countries with lower resources. The objective of this study is to report the first institutional dosimetric and clinical data on intracavitary electronic brachytherapy.Methods: A total of 25 patients with histologically proven cervical cancer stage IB-IVA were treated with concurrent chemoradiotherapy and electronic brachytherapy. The patients were followed up for a median of 12 months (range 6–24). Toxicity was evaluated by the radiation oncologist and gynecologist on each visit and scored by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Results: All patients completed the treatment successfully with a median overall treatment time (OTT) of 52 days (range 39–89). The desired target coverage was achieved in all patients, and the dose limits for the organs at risk were achieved in 88% of the patients. No Grade 3 toxicities occurred. A total of 84% of the patients achieved local control in the cervix, and a complete response was noted in 72% of the patients.Conclusions: Electronic brachytherapy provides the option to deliver a high dose of radiation to the uterine cervix without leading to severe toxicity. Further improvements to the treatment protocol could provide better locoregional and systemic control of the disease. Studies with larger cohorts and longer follow-up are necessary.
背景/目的：影像引导自适应近距离放射治疗是局部晚期宫颈癌的标准治疗方式。然而，在资源相对匮乏的国家，基于同位素的近距离放射治疗的可及性有限。本研究旨在报告首个关于腔内电子近距离放射治疗的机构剂量学和临床数据。 方法：共纳入25例经组织学证实为IB-IVA期宫颈癌患者，接受同步放化疗及电子近距离放射治疗。患者中位随访时间为12个月（范围6-24个月）。每次随访时由放射肿瘤科医生和妇科医生评估毒性反应，并采用不良事件通用术语标准（CTCAE）5.0版进行分级。 结果：所有患者均顺利完成治疗，中位总治疗时间（OTT）为52天（范围39-89天）。所有患者均达到预期靶区覆盖，88%的患者达到危及器官剂量限值要求。未发生3级毒性反应。84%的患者实现宫颈局部控制，72%的患者达到完全缓解。 结论：电子近距离放射治疗为宫颈癌患者提供了可实施高剂量照射而不导致严重毒性的治疗选择。治疗方案的进一步优化有望提升疾病的局部区域控制和全身控制效果。未来需要更大样本量和更长随访时间的研究加以验证。
肿瘤(癌症)患者之家